Management of Common Bile Duct (CBD) Stones at Laparoscopic Cholecystectomy
Choledocholithiasis, Cholelithiasis
About this trial
This is an interventional educational/counseling/training trial for Choledocholithiasis focused on measuring Cholecystectomy, Cholangiopancreatography, Endoscopic Retrograde
Eligibility Criteria
Inclusion Criteria: The patient must be able to give informed consent preoperatively (i.e. elective procedures only) Patients at higher than normal risk of having CBD stones identified at OC. For example: *CBD stones identified at ultrasound; *Wide CBD (>6mm) at ultrasound; *Previous, recent, current cholangitis, jaundice, or biliary pancreatitis; or *Abnormal AST and ALT levels (>2 times normal). Exclusion Criteria: Pregnancy at time of surgery Patients not fit for surgery. For example: *Those with acute cholecystitis or persistent obstructive jaundice; *Patients who have had a previous ERCP and sphincterotomy; or *Patients in whom intervention was not technically possible (eg. previous Billroth II gastrectomy).
Sites / Locations
- Bankstown-Lidcombe Hospital
- Royal Prince Alfred Hospital
- Dubbo Base Hospital
- Gosford Hospital
- Blue Mountains District ANZAC Memorial Hospital
- Nepean Hospital
- St George Hospital
- Liverpool Hospital
- John Hunter Hospital
- Prince of Wales Hospital
- Royal North Shore Hospital
- Westmead Hospital
- Hawkesbury District Health Service